Precigen (PGEN) Land & Improvements (2013 - 2026)
Precigen (PGEN) posted quarterly Land & Improvements of $2.4 million for Q1 2026, up 1374.39% year-over-year from $164000.0 in Q1 2025, and little changed quarter-over-quarter from $2.4 million in Q4 2025.
Analysis
Precigen (PGEN) Land & Improvements (2013 - 2026) Analysis & Trends
Precigen (PGEN) has reported Land & Improvements for 14 consecutive years, with $2.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Land & Improvements rose 1374.39% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (up 1374.39% YoY), while the FY2025 annual figure was $2.4 million, down 24.42% from the prior year.
- Land & Improvements held at $2.4 million in Q1 2026 per PGEN's latest filing, from $2.4 million in the prior quarter.
- Across five years, Land & Improvements topped out at $5.2 million in Q1 2022 and bottomed at $164000.0 in Q2 2022.
- Historically, Land & Improvements has averaged $1.8 million across 5 years, with a median of $164000.0 in 2022.
- Annual changes were most pronounced in 2022 — Land & Improvements sank 97.15% — and 2026, when it soared 1374.39%.
- Precigen's Land & Improvements stood at $4.6 million in 2022, then slipped by 24.18% to $3.5 million in 2023, then decreased by 7.89% to $3.2 million in 2024, then slipped by 24.42% to $2.4 million in 2025, then grew by 0.42% to $2.4 million in 2026.
- Business Quant data shows PGEN's Land & Improvements at $2.4 million in Q1 2026, $2.4 million in Q4 2025, and $164000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | 2.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.47 Mn |
| Mar 31, 2026 | 2.42 Mn |
| Dec 31, 2025 | 2.41 Mn |
| Sep 30, 2025 | 2.90 Mn |
| Jun 30, 2025 | 2.28 Mn |
| Mar 31, 2025 | 3.21 Mn |
| Dec 31, 2024 | 3.19 Mn |
| Sep 30, 2024 | 3.19 Mn |
| Jun 30, 2024 | 3.21 Mn |
| Mar 31, 2024 | 3.48 Mn |
| Dec 31, 2023 | 3.46 Mn |
| Sep 30, 2023 | 3.68 Mn |
| Jun 30, 2023 | 4.64 Mn |
| Mar 31, 2023 | 4.61 Mn |
| Dec 31, 2022 | 4.56 Mn |
| Sep 30, 2022 | 4.52 Mn |
| Jun 30, 2022 | 4.54 Mn |
| Mar 31, 2022 | 11.12 Mn |
| Dec 31, 2021 | 4.82 Mn |
| Sep 30, 2021 | 9.84 Mn |